Epstein-Barr virus / dpa
Freiburg Several medical companies have presented a new guideline for the diagnosis, prevention and treatment of viral infections in organ and stem cell transplant patients. It is aimed at patients and outpatients involved in the care of patients before and after organ and allogeneic stem cell transplants.
The Society for Virology (GfV) and the German Association for the Control of Viral Diseases (DVV) in collaboration with 18 other specialized companies worked according to the guidelines.
Due to the severe therapy-related immunosuppression, transplanted patients are particularly at risk for viral infections. Therefore, before the transplant is a screening, the procedure after the procedure is a risk-adjusted monitoring of patients. Based on this diagnosis, it is possible to use targeted antiviral drugs to prevent or treat a condition.
Based on current scientific findings, recommendations have now been developed for methodology, frequency and extent of virologic diagnostics, and for drug and immunocellular therapy of viral infections for the guideline.
The guideline contains individual chapters on frequent and particularly risky pathogens for transplant patients (herpes simplex virus 1 and 2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus, human herpes virus 6, parvovirus B19, BK polyomavirus), and adenovirus. and respiratory virus. In collaboration with virological and clinical experts, the recommendations are summarized in virus virus tables.
In addition, the guideline addresses modern methods of resistance testing, new antiviral drugs, and evidence-based T-cell diagnostics and therapy. In addition, the authors identified additional research needs, particularly to improve the long-term prognosis of patients after organ and stem cell transplantation. © hil / sb / aerzteblatt.de